End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
17.55
CNY
|
-2.50%
|
|
-3.36%
|
-31.53%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,424
|
4,663
|
5,410
|
7,626
|
6,237
|
4,082
|
Enterprise Value (EV)
1 |
3,396
|
4,715
|
5,501
|
7,420
|
6,309
|
4,338
|
P/E ratio
|
202
x
|
416
x
|
366
x
|
-206
x
|
-48.9
x
|
-11.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.51
x
|
11.2
x
|
14.7
x
|
20.6
x
|
16.2
x
|
9.66
x
|
EV / Revenue
|
8.44
x
|
11.4
x
|
14.9
x
|
20
x
|
16.4
x
|
10.3
x
|
EV / EBITDA
|
143
x
|
207
x
|
151
x
|
-251
x
|
-35.8
x
|
-30.9
x
|
EV / FCF
|
-13.6
x
|
-61.3
x
|
-641
x
|
-34.1
x
|
-23.6
x
|
-17.8
x
|
FCF Yield
|
-7.37%
|
-1.63%
|
-0.16%
|
-2.93%
|
-4.23%
|
-5.63%
|
Price to Book
|
6.13
x
|
8.25
x
|
9.38
x
|
7.31
x
|
6.72
x
|
7.9
x
|
Nbr of stocks (in thousands)
|
141,211
|
140,000
|
140,000
|
158,777
|
159,267
|
159,267
|
Reference price
2 |
24.25
|
33.31
|
38.64
|
48.03
|
39.16
|
25.63
|
Announcement Date
|
4/1/19
|
3/25/20
|
3/31/21
|
4/21/22
|
4/20/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
402.4
|
414.9
|
368.5
|
370.4
|
385.8
|
422.7
|
EBITDA
1 |
23.79
|
22.81
|
36.4
|
-29.58
|
-176.1
|
-140.2
|
EBIT
1 |
1.461
|
0.9361
|
-0.6712
|
-81.17
|
-234.3
|
-211.9
|
Operating Margin
|
0.36%
|
0.23%
|
-0.18%
|
-21.91%
|
-60.73%
|
-50.13%
|
Earnings before Tax (EBT)
1 |
11.76
|
12.15
|
15.35
|
-45.69
|
-163.4
|
-298
|
Net income
1 |
16.48
|
10.74
|
14.82
|
-34.89
|
-127.4
|
-348.6
|
Net margin
|
4.1%
|
2.59%
|
4.02%
|
-9.42%
|
-33.03%
|
-82.46%
|
EPS
2 |
0.1200
|
0.0800
|
0.1056
|
-0.2335
|
-0.8004
|
-2.189
|
Free Cash Flow
1 |
-250.4
|
-76.92
|
-8.581
|
-217.3
|
-267.1
|
-244.1
|
FCF margin
|
-62.22%
|
-18.54%
|
-2.33%
|
-58.65%
|
-69.24%
|
-57.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/1/19
|
3/25/20
|
3/31/21
|
4/21/22
|
4/20/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
51.9
|
91.6
|
-
|
72.6
|
256
|
Net Cash position
1 |
27.9
|
-
|
-
|
206
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
2.277
x
|
2.516
x
|
-
|
-0.4121
x
|
-1.829
x
|
Free Cash Flow
1 |
-250
|
-76.9
|
-8.58
|
-217
|
-267
|
-244
|
ROE (net income / shareholders' equity)
|
3%
|
2.21%
|
2.86%
|
-4.19%
|
-14%
|
-49.2%
|
ROA (Net income/ Total Assets)
|
0.11%
|
0.07%
|
-0.04%
|
-4.14%
|
-9.96%
|
-8.52%
|
Assets
1 |
14,372
|
16,081
|
-33,616
|
843.3
|
1,280
|
4,092
|
Book Value Per Share
2 |
3.960
|
4.040
|
4.120
|
6.570
|
5.830
|
3.240
|
Cash Flow per Share
2 |
0.6100
|
0.6700
|
0.9700
|
2.480
|
1.500
|
1.270
|
Capex
1 |
229
|
67.8
|
54.5
|
174
|
196
|
201
|
Capex / Sales
|
56.97%
|
16.35%
|
14.78%
|
47.08%
|
50.8%
|
47.61%
|
Announcement Date
|
4/1/19
|
3/25/20
|
3/31/21
|
4/21/22
|
4/20/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -31.53% | 396M | | +38.30% | 705B | | +32.82% | 583B | | -3.74% | 364B | | +19.92% | 332B | | +4.91% | 291B | | +16.64% | 238B | | -4.13% | 210B | | +10.63% | 209B | | +8.83% | 169B |
Other Pharmaceuticals
|